RGRX

 
Common Stock SEC Reporting - Current
OTCQB
Verified Company Profile 1/19/2018
Contact Info
  • 15245 Shady Grove Road - Suite 470
  • Rockville, MD 20850

Business Description


 
Financial Reporting/Disclosure
Reporting Status U.S. Reporting: SEC Reporting
Audited Financials Audited
Latest Report Sep 30, 2017 10-Q
CIK 0000707511
Fiscal Year End 12/31
OTC Marketplace OTCQB
Profile Data
SIC - Industry Classification 2834 - Pharmaceutical preparations
Incorporated In: DE, USA
Year of Inc. 1982
Employees Not Available
Company Officers/Contacts
J.J. Finkelstein President, CEO
Dane Saglio CFO
Lori Smith Administrator
Company Directors
Allan L. Goldstein Chairman
Mauro Bove
Don Elsey
Joseph C. McNay
Service Providers
Accounting/Auditing Firm
CohnReznick LLP
8045 Leesburg Pike
Suite 240
Vienna, VA, 22182
United States
 
Securities Counsel
Avisen
901 Marquette Avenue
Suite 1675
Minneaopolis, MN, 55402
United States
 
Investor Relations Firm
PCG Advisory Group
535 Fifth Avenue
24th Floor
New York, NY, 10017
United States
 
Company History
  • Formerly=Alpha 1 Biomedicals, Inc. until 12-00
RGRX Security Details
Share Structure
Market Value1 $30,741,117 a/o Jan 22, 2018
Authorized Shares 200,000,000 a/o Mar 31, 2017
Outstanding Shares 109,789,703 a/o Nov 10, 2017
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 45,819,317 a/o Jun 30, 2016
Par Value 0.001
Shareholders
Shareholders of Record 745 a/o Apr 11, 2016
Short Selling Data
Short Interest 280 (-78.61%)
Dec 15, 2017
Significant Failures to Deliver No

1Market Value calculated only for respective security